The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Drug Metabolism in the Liver
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Cytochrome P-450: Structure, Mechanism, and Biochemistry
de Montellano, O., & Paul, R. (1986) · Medical Entomology and Zoology · Cited by 2,663
Cytochrome P450: Structure, mechanism, and biochemistry
Pryor, W. A. (1996) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(96)83807-x · Cited by 1,598
An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway
Kliewer, S. A., Moore, J. T., Wade, L., Staudinger, J. L., Watson, M. A., Jones, S. A., McKee, D. D., Oliver, B. B., Willson, T. M., Zetterström, R. H., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)80900-9 · Cited by 1,539
Nelson, D. R. (2009) · Human Genomics · doi:10.1186/1479-7364-4-1-59 · Cited by 1,014
Hediger, M. A., Romero, M. F., Peng, J.-B., Rolfs, A., Takanaga, H., & Bruford, E. A. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1192-y · Cited by 985
Identification of a human nuclear receptor defines a new signaling pathway for CYP 3 A induction
Bertilsson, G., Heidrich, J., Svensson, K., Åsman, M., Jendeberg, L., Sydow-Bäckman, M., Ohlsson, R., Postlind, H., Blomquist, P., & Berkenstam, A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.21.12208 · Cited by 872
Clinical Pharmacokinetics of Mycophenolate Mofetil
Bullingham, R. E. S., Nicholls, A. J., & Kamm, B. R. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199834060-00002 · Cited by 839
Inhibition and Induction of Cytochrome P450 and the Clinical Implications
Lin, J. H., & Lu, A. Y. H. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835050-00003 · Cited by 829
Ding, X., & Kaminsky, L. S. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140251 · Cited by 822
Honkakoski, P., Zelko, I., Sueyoshi, T., & Negishi, M. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.10.5652 · Cited by 700
Iyer, L., King, C. D., Whitington, P. F., Green, M. D., Roy, S. K., Tephly, T. R., Coffman, B. L., & Ratain, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci915 · Cited by 686
Lown, K. S., Mayo, R. R., Leichtman, A. B., Hsiao, H.-L., Turgeon, D. K., Schmiedlin-Ren, P., Brown, M. B., Guo, W., Rossi, S. J., Benet, L. Z., et al. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90027-8 · Cited by 680
The effect of age upon liver volume and apparent liver blood flow in healthy man
Wynne, H. A., Cope, L. H., Mutch, E., Rawlins, M. D., Woodhouse, K. W., & James, O. F. W. (1989) · Hepatology · doi:10.1002/hep.1840090222 · Cited by 652
Clinical relevance of genetic polymorphisms in the human CYP2C subfamily
Goldstein, J. A. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01499.x · Cited by 617
Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis
Weltman, M. D., Farrell, G. C., Hall, P., Ingelman-Sundberg, M., & Liddle, C. (1998) · Hepatology · doi:10.1002/hep.510270121 · Cited by 614
Chan, L. M. S., Lowes, S., & Hirst, B. H. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2003.07.003 · Cited by 582
Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs
Zhou, S., Yung Chan, S., Cher Goh, B., Chan, E., Duan, W., Huang, M., & McLeod, H. L. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544030-00005 · Cited by 517
Androstane metabolites bind to and deactivate the nuclear receptor CAR-β
Forman, B. M., Tzameli, I., Choi, H.-S., Chen, J., Simha, D., Seol, W., Evans, R. M., & Moore, D. D. (1998) · Nature · doi:10.1038/26996 · Cited by 476
Brüggemann, R. J. M., Alffenaar, J. C., Blijlevens, N. M. A., Billaud, E. M., Kosterink, J. G. W., Verweij, P. E., & Burger, D. M. (2009) · Clinical Infectious Diseases · doi:10.1086/598327 · Cited by 457
The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs
Shugarts, S., & Benet, L. Z. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9924-0 · Cited by 438
Saito, C., Zwingmann, C., & Jaeschke, H. (2010) · Hepatology · doi:10.1002/hep.23267 · Cited by 430
Pharmacokinetics of drugs in pregnancy
Feghali, M., Venkataramanan, R., & Caritis, S. (2015) · Seminars in Perinatology · doi:10.1053/j.semperi.2015.08.003 · Cited by 375
Self-citationJakobsson, P., Morgenstern, R., Mancini, J., Ford‐Hutchinson, A., & Persson, B. (1999) · Protein Science · doi:10.1110/ps.8.3.689 · Cited by 365
Pavek, P., & Dvorak, Z. (2008) · Current Drug Metabolism · doi:10.2174/138920008783571774 · Cited by 327
Coffman, B. L., King, C. D., Rios, G. R., & Tephly, T. R. (1998) · PubMed · Cited by 322
Furuya, H., Fernandez-Salguero, P., Gregory, W., Taber, H., Steward, A., Gonzalez, F. J., & Idle, J. R. (1995) · Pharmacogenetics · doi:10.1097/00008571-199512000-00008 · Cited by 278
Bioavailability Improvement of Mycophenolic Acid Through Amino Ester Derivatization
Lee, W. A., Gu, L., Miksztal, A. R., Chu, N., Leung, K., & Nelson, P. H. (1990) · Pharmaceutical Research · doi:10.1023/a:1015828802490 · Cited by 254
Isoherranen, N., & Thummel, K. E. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.050245 · Cited by 239
Fricker, G., Drewe, J., Huwyler, J., Gutmann, H., & Beglinger, C. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb15612.x · Cited by 223
Achour, B., Barber, J., & Rostami-Hodjegan, A. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058834 · Cited by 212
Drug metabolism and pharmacokinetics
Benedetti, M. S., Whomsley, R., Poggesi, I., Cawello, W., Mathy, F.-X., Delporte, M.-L., Papeleu, P., & Watelet, J.-B. (2009) · Drug Metabolism Reviews · doi:10.1080/10837450902891295 · Cited by 201
The UCSF-FDA TransPortal: A Public Drug Transporter Database
Morrissey, K. M., Wen, C. C., Johns, S. J., Zhang, L., Huang, S.-M., & Giacomini, K. M. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.44 · Cited by 169
Köhle, C., & Bock, K. W. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.05.020 · Cited by 157
Dostálek, M., Court, M. H., Yan, B., & Akhlaghi, F. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01270.x · Cited by 139
Inhibition of Sulfotransferases by Xenobiotics
Wang, L., & James, M. O. (2005) · Current Drug Metabolism · doi:10.2174/138920006774832596 · Cited by 139
Woodhouse, K. W., & Wynne, H. (1988) · Clinical Pharmacokinetics · doi:10.2165/00003088-198815050-00002 · Cited by 137
CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease
Woolsey, S., Mansell, S. E., Kim, R. B., Tirona, R. G., & Beaton, M. D. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.065979 · Cited by 135
Hardwick, R. N., Ferreira, D. W., More, V. R., Lake, A. D., Lu, Z. J., Manautou, J. E., Slitt, A. L., & Cherrington, N. J. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.048439 · Cited by 134
In vitro metabolism of cyclosporine A by human kidney CYP3A5
Dai, Y., Iwanaga, K., Lin, Y. S., Hébert, M. F., Davis, C. L., Huang, W., Kharasch, E. D., & Thummel, K. E. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.07.012 · Cited by 133
Gender as a Risk Factor for Adverse Events to Medications
Kando, J. C., Yonkers, K. A., & Cole, J. O. (1995) · Drugs · doi:10.2165/00003495-199550010-00001 · Cited by 128
Cytochrome P450 in Cancer Susceptibility and Treatment
Mittal, B., Tulsyan, S., Kumar, S., Mittal, R. D., & Agarwal, G. (2015) · Advances in clinical chemistry · doi:10.1016/bs.acc.2015.06.003 · Cited by 127
Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids
Dvořák, Z., & Pávek, P. (2010) · Drug Metabolism Reviews · doi:10.3109/03602532.2010.484462 · Cited by 117
Peters, S. A., Jones, C. R., Ungell, A.-L. B., & Hatley, O. J. D. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0351-6 · Cited by 115
Prediction of cytochrome P450 mediated metabolism
Olsen, L., Oostenbrink, C., & Jørgensen, F. S. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.04.020 · Cited by 110
Mizuma, T. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.05.044 · Cited by 106
Schuck, R. N., Zha, W., Edin, M. L., Gruzdev, A., Vendrov, K. C., Miller, T. M., Xu, Z., Lih, F. B., DeGraff, L. M., Tomer, K. B., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110162 · Cited by 105
Guenthner, T. M., & Nebert, D. W. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38335-7 · Cited by 95
The Effects of CKD on Cytochrome P450–Mediated Drug Metabolism
Ladda, M. A., & Goralski, K. B. (2016) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2015.10.002 · Cited by 91
Wynne, H. (2005) · The Journal of the British Menopause Society · doi:10.1258/136218005775544589 · Cited by 88
Jain, A. B., Venkataramanan, R., Eghtesad, B., Marcos, A., Ragni, M., Shapiro, R., Rafail, A. B., & Fung, J. J. (2003) · Liver Transplantation · doi:10.1053/jlts.2003.50171 · Cited by 85
Self-citationMediation of donor–acceptor distance in an enzymatic methyl transfer reaction
Zhang, J., Kulik, H. J., Martínez, T. J., & Klinman, J. P. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1506792112 · Cited by 78
Drug Metabolism and Pharmacokinetics Quick Guide
Khojasteh, S. C., Wong, H. H., & Hop, C. E. C. A. (2011) · Springer eBooks · doi:10.1007/978-1-4419-5629-3 · Cited by 75
Chen, J., Zhao, K., & Chen, C. (2014) · PubMed Central · doi:10.3978/j.issn.2305-5839.2013.03.02 · Cited by 73
Liow, J., Lu, S., McCarron, J. A., et al. (2006) · Synapse · doi:10.1002/syn.20348 · Cited by 71
Effect of CKD and Dialysis Modality on Exposure to Drugs Cleared by Nonrenal Mechanisms
Thomson, A. B. R., Nolin, T. D., Velenosi, T. J., Feere, D. A., Knauer, M. J., Asher, L. J., House, A. A., & Urquhart, B. L. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.09.015 · Cited by 68
Iyer, K. R., & Sinz, M. (1999) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(99)00007-1 · Cited by 68
Drug–drug interactions of antifungal agents and implications for patient care
Gubbins, P. O., & Amsden, J. R. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.13.2231 · Cited by 66
Voriconazole therapeutic drug monitoring: focus on safety
Pasqualotto, A. C., Xavier, M. O., Andreolla, H. F., & Linden, R. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903485637 · Cited by 65
Antonini, A., Abbruzzese, G., Barone, P., Bonuccelli, U., Lopiano, L., Onofrj, M., Zappia, M., & Quattrone, A. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s2404 · Cited by 60
Tischer, S. M., & Fontana, R. J. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.013 · Cited by 60
Terada, T., & Hira, D. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-015-1061-4 · Cited by 53
Zhao, Y., Hébert, M. F., & Venkataramanan, R. (2014) · Seminars in Perinatology · doi:10.1053/j.semperi.2014.08.011 · Cited by 52
Self-citationAltered Pharmacokinetics of Voriconazole in a Patient with Liver Cirrhosis
Weiler, S., Zoller, H., Graziadei, I. W., Vogel, W., Bellmann‐Weiler, R., Joannidis, M., & Bellmann, R. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00791-07 · Cited by 49
Joy, M. S., Frye, R. F., Nolin, T. D., Roberts, B. V., La, M. K., Wang, J., Brouwer, K. L. R., Dooley, M. A., & Falk, R. J. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1347 · Cited by 41
Inhibitory effects of polyphenolic compounds on human arylamineN-acetyltransferase 1 and 2
Kukongviriyapan, V., Phromsopha, N., Tassaneeyakul, W., Kukongviriyapan, U., Sripa, B., Hahnvajanawong, V., & Bhudhisawasdi, V. (2006) · Xenobiotica · doi:10.1080/00498250500489901 · Cited by 40
All‐trans Retinoic Acid Induction of Sulfotransferases
Maiti, S., Chen, X., & Chen, G. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto960107.x · Cited by 37
Drug Metabolism: Current Concepts
Ionescu, C. M., & Caira, M. R. (2010) · Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) · doi:10.1007/1-4020-4142-x · Cited by 34
Drug Metabolism and Pharmacokinetics Quick Guide
Morris, M. E. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.35 · Cited by 33
Chen, Q., Li, X., Zhao, J., Bi, X., Li, Z., Huang, Z., Zhang, Y., Zhou, J., Zhao, H., & Cai, J. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4289 · Cited by 23
Liu, Z., Chen, Y., Tao, R., Jing, X., Meng, J., & Yong, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107057 · Cited by 18
Hepatotoxicity and Drug Interactions in Liver Transplant Candidates and Recipients
Parikh, N. D., & Levitsky, J. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.07.013 · Cited by 9
Cited by
Cytochrome P450 Enzymes and Drug Metabolism in Humans
Zhao, M., Ma, J., Li, M., Zhang, Y., Jiang, B., Zhao, X., Huai, C., Shen, L., Zhang, N., He, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312808 · Cited by 1,070
Esteves, F., Rueff, J., & Kranendonk, M. (2021) · Journal of Xenobiotics · doi:10.3390/jox11030007 · Cited by 512
Georgiou-Siafis, S. K., & Tsiftsoglou, A. S. (2023) · Antioxidants · doi:10.3390/antiox12111953 · Cited by 294
New insights on bioactivities and biosynthesis of flavonoid glycosides
Yang, B., Liu, H., Yang, J., Gupta, V. K., & Jiang, Y. (2018) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2018.07.006 · Cited by 277
Drug induced liver injury – a 2023 update
Allison, R., Guraka, A., Shawa, I. T., Tripathi, G., Moritz, W., & Kermanizadeh, A. (2023) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937404.2023.2261848 · Cited by 167
Metadata
- Authors
- Almazroo, O. A., Miah, M. K., & Venkataramanan, R.
- Venue
- Clinics in Liver Disease
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 21
- Issue
- 1
- Pages
- 1-20
- ISSN
- 1089-3261 (ISSN-L)
- OpenAlex
- W2538201653
- Cited by
- 681
- References
- 72
- FWCI
- 25.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.